Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vs Standard-dose Rabeprazole for GERD with Extra-esophageal Manifestations
NCT04001400Phase 3Completed
- Sponsor
- Seoul National University Hospital
- Start
- Oct 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rabeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Effective improvement of symptoms at 8 weeks. Started Oct 2012; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04001400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001400.